MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics is positioned favorably because agenT-797 targets ARDS, a fatal lung condition with ~40% mortality in ventilated moderate-to-severe cases and no FDA-approved or late-stage immunotherapy peer, creating a large unmet need where even modest efficacy could be highly meaningful. Its ~124-patient Ph2b is designed with an efficient win-ratio endpoint of alive and free of VV-ECMO at Day 14 followed by Day-28 mortality, an active U.S. IND, and FDA-cleared randomized Ph2 momentum that materially de-risks the path to a seamless Ph2/3 and potential 1Q29 BLA. The bull case is further strengthened by non-dilutive funding sources, paid named-patient receipts in Brazil, and a model focused on ARDS alone with ~9K treated U.S. patients by 2035 at about $50K per infusion, implying attractive commercial leverage if the program succeeds.

MiNK Therapeutics is a clinical-stage, single-asset story whose outlook is weighed down by unresolved clinical, regulatory, and commercialization risks, especially given that no drug has improved ARDS mortality in 25 years and the field remains mechanistically fragmented. The company’s lead asset, agenT-797, still faces uncertain safety and efficacy outcomes, and the cited 20% probability of success for gastric cancer highlights how limited the current valuation case is. Financially, with about $8.8M in cash and cash equivalents at 6/30/26 and an assumed need for roughly $30M more through 2038, it likely must raise additional capital before profitability, increasing dilution and execution risk.